{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T10:15:49Z","timestamp":1794651349326,"version":"4.9.1"},"reference-count":23,"publisher":"American Society of Hematology","issue":"16","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,8,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Tacrolimus (Tac)\/methotrexate (MTX) is standard graft-versus-host disease (GVHD) prophylaxis; however, is associated with several toxicities. Tac, reduced-dose MTX (mini-MTX), and mycophenolate mofetil (MMF) have been used but never compared with standard MTX. We performed a randomized trial comparing Tac\/MTX (full-MTX) with Tac\/mini-MTX\/MMF (mini-MTX\/MMF) for GVHD prevention after allogeneic hematopoietic cell transplantation (HCT). Patients (pts) receiving first myeloablative HCT using an 8\/8 HLA-matched donor were eligible. Primary end points were incidence of acute GVHD (aGVHD), mucositis, and engraftment. Secondary end points included chronic GVHD (cGVHD), organ toxicity, infection, relapse, nonrelapse mortality (NRM), and overall survival (OS). Ninety-six pts were randomly assigned to full-MTX (N = 49) or mini-MTX (N\u00a0=\u00a047). The majority (86%) used bone marrow grafts. There was no significant difference in grade 2-4 aGVHD (28% mini-MTX\/MMF vs 27% full-MTX;\u00a0P\u00a0= .41); however higher incidence of grade 3-4 aGVHD (13% vs 4%;\u00a0P\u00a0= .07) with mini-MTX\/MMF. Pts receiving mini-MTX\/MMF had lower grade 3 or 4 mucositis and faster engraftment. There were no differences in moderate-to-severe cGVHD at 1 year or infections. Pts receiving mini-MTX\/MMF experienced less nephrotoxicity and respiratory failure. There was no difference in the 1-year relapse (19% vs 21%;\u00a0P\u00a0= .89) and OS (72% vs 71%;\u00a0P\u00a0= .08), and mini-MTX\/MMF was associated with lower but nonsignificant NRM (11% vs 22%;\u00a0P\u00a0= .06). Compared with full-MTX, mini-MTX\/MMF was associated with no difference in grade 2-4 aGVHD and a more favorable toxicity profile. The higher severe aGVHD warrants further study to optimize this regimen. The trial was registered at www.clinicaltrials.gov as #NCT01951885.<\/jats:p>","DOI":"10.1182\/bloodadvances.2023010310","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T16:43:10Z","timestamp":1687624990000},"page":"4505-4513","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":16,"title":["Tacrolimus\/methotrexate vs tacrolimus\/reduced-dose methotrexate\/mycophenolate for graft-versus-host disease prevention"],"prefix":"10.1182","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1252-6539","authenticated-orcid":false,"given":"Betty K.","family":"Hamilton","sequence":"first","affiliation":[{"name":"1Department of Hematology and Medical Oncology, Blood and Marrow Transplantation, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Rybicki","sequence":"additional","affiliation":[{"name":"2Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9593-919X","authenticated-orcid":false,"given":"Hong","family":"Li","sequence":"additional","affiliation":[{"name":"2Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Lucas","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, Blood and Marrow Transplantation, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Corrigan","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, Blood and Marrow Transplantation, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matt","family":"Kalaycio","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, Blood and Marrow Transplantation, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Sobecks","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, Blood and Marrow Transplantation, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rabi","family":"Hanna","sequence":"additional","affiliation":[{"name":"3Department of Pediatric Hematology, Oncology and Blood and Marrow Transplantation, Pediatric Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth J.","family":"Rotz","sequence":"additional","affiliation":[{"name":"3Department of Pediatric Hematology, Oncology and Blood and Marrow Transplantation, Pediatric Institute, Cleveland Clinic, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2559-563X","authenticated-orcid":false,"given":"Robert M.","family":"Dean","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, Blood and Marrow Transplantation, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3422-1309","authenticated-orcid":false,"given":"Aaron T.","family":"Gerds","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, Blood and Marrow Transplantation, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Jagadeesh","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, Blood and Marrow Transplantation, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1997-3799","authenticated-orcid":false,"given":"Claudio","family":"Brunstein","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, Blood and Marrow Transplantation, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig S.","family":"Sauter","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Medical Oncology, Blood and Marrow Transplantation, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Copelan","sequence":"additional","affiliation":[{"name":"4Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7082-891X","authenticated-orcid":false,"given":"Navneet S.","family":"Majhail","sequence":"additional","affiliation":[{"name":"5Sarah Cannon Transplant and Cellular Therapy Network, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"issue":"11","key":"2023082115042453800_bib1","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.bbmt.2007.08.005","article-title":"Blood and marrow transplant clinical trials network state of the science symposium 2007","volume":"13","author":"Ferrara","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"2023082115042453800_bib2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1182\/asheducation.V2012.1.251.3798879","article-title":"Are we making progress in GVHD prophylaxis and treatment?","volume":"2012","author":"Pavletic","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"8","key":"2023082115042453800_bib3","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jtct.2022.05.002","article-title":"Are we making PROGRESS in preventing graft-versus-host disease and improving clinical outcomes? Impact of BMT CTN 1301 study results on clinical practice","volume":"28","author":"Hamilton","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"2023082115042453800_bib4","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1038\/bcj.2015.70","article-title":"Does day 11 omission of methotrexate due to toxicity influence the outcome in myeloablative hematopoietic cell transplant? Results from a single-center retrospective cohort study","volume":"5","author":"Hamilton","year":"2015","journal-title":"Blood Cancer J"},{"issue":"11","key":"2023082115042453800_bib5","doi-asserted-by":"crossref","first-page":"4383","DOI":"10.1182\/blood.V88.11.4383.4383","article-title":"Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after matched unrelated donor marrow transplantation","volume":"88","author":"Przepiorka","year":"1996","journal-title":"Blood"},{"issue":"7","key":"2023082115042453800_bib6","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/sj.bmt.1701983","article-title":"Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation","volume":"24","author":"Przepiorka","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2023082115042453800_bib7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann Intern Med"},{"issue":"4","key":"2023082115042453800_bib8","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1007\/s12185-009-0306-5","article-title":"Mycophenolate mofetil combined with tacrolimus and minidose methotrexate after unrelated donor bone marrow transplantation with reduced-intensity conditioning","volume":"89","author":"Mizumoto","year":"2009","journal-title":"Int J Hematol"},{"issue":"6","key":"2023082115042453800_bib9","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.bbmt.2018.01.002","article-title":"Blood and marrow transplant clinical trials network report on the development of novel endpoints and selection of promising approaches for graft-versus-host disease prevention trials","volume":"24","author":"Pasquini","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2023082115042453800_bib10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2023082115042453800_bib11","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"2023082115042453800_bib12","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the disease risk index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"3","key":"2023082115042453800_bib13","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.bmt.1703616","article-title":"Omission of day\u00a0+11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease","volume":"30","author":"Kumar","year":"2002","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2023082115042453800_bib14","doi-asserted-by":"crossref","first-page":"119.e1","DOI":"10.1016\/j.jtct.2022.11.006","article-title":"Significance of omitting day 11 mini-dose methotrexate for GVHD prophylaxis after unrelated bone marrow transplantation","volume":"29","author":"Nakamura","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"2023082115042453800_bib15","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","article-title":"Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)","volume":"6","author":"Bolanos-Meade","year":"2019","journal-title":"Lancet Haematol"},{"issue":"11","key":"2023082115042453800_bib16","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1182\/blood-2010-08-302109","article-title":"Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria","volume":"117","author":"Flowers","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2023082115042453800_bib17","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2011-06-364265","article-title":"Risk factors for acute GVHD and survival after hematopoietic cell transplantation","volume":"119","author":"Jagasia","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2023082115042453800_bib18","first-page":"288","article-title":"Blood, marrow transplant clinical trials N. peripheral-blood versus bone marrow stem cells","volume":"368","author":"Anasetti","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 3","key":"2023082115042453800_bib19","article-title":"Calcineurin inhibitor-free graft-versus-host disease (GVHD) prophylaxis in hematopoietic cell transplantation (HCT) with myeloablative conditioning regimens (MAC) and HLA-matched donors: results of the BMT CTN 1301 PROGRESS II trial","volume":"27","author":"Pasquini","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"2023082115042453800_bib20","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1080\/10428194.2022.2032036","article-title":"Impact of omitting post-transplant minidose-methotrexate doses in allogeneic hematopoietic cell transplantation","volume":"63","author":"Lin","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2023082115042453800_bib21","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.clpt.2005.08.009","article-title":"Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation","volume":"78","author":"Jacobson","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"2023082115042453800_bib22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/ejh.13537","article-title":"Weight-based mycophenolate mofetil dosing predicts acute GVHD and relapse after allogeneic hematopoietic cell transplantation","volume":"106","author":"Bejanyan","year":"2021","journal-title":"Eur J Haematol"},{"issue":"4","key":"2023082115042453800_bib23","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.21.02293","article-title":"Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies","volume":"40","author":"Luznik","year":"2022","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/16\/4505\/2072574\/blooda_adv-2023-010310-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/16\/4505\/2072574\/blooda_adv-2023-010310-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,21]],"date-time":"2023-08-21T15:08:23Z","timestamp":1692630503000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/16\/4505\/496495\/Tacrolimus-methotrexate-vs-tacrolimus-reduced-dose"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":23,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2023,8,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010310","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,11]]}}}